Iceland· IS-920181
Dipentum
A olsalazine product containing olsalazinum inn natríum, registered in Iceland by Atnahs Pharma Netherlands B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Olsalazine is registered in 11 of 19 countries.
Countries holding a registration under ATC A07EC03 (olsalazine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 5 of them publish a price we can compare per daily dose
Olsalazine · ATC A07EC03
11 / 19 countries
- Canada
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of olsalazine costs, country by country.
Normalised to the WHO defined daily dose (1 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Olsalazine · price per daily dose (1 g)
USD · FX 28 Sept 2026
- FR France$1.44
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Olsalazinum INN natríum
- Manufacturer
- Atnahs Pharma Netherlands B.V.
- Country
- Iceland (IS)
- ATC code
- A07EC03
- ATC class
- Olsalazine
- Defined daily dose
- 1 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
110 interactions on record for olsalazine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Olsalazine · interactions on record
110 records
- 15 severe
- 93 moderate
- 2 minor
Most severe, free to view
- CidofovirJ05AB12severe
- Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
- Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Olsalazine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomDipentum 500mg tabletsUCB Pharma Ltd
- NorwayDipentumAtnahs Pharma Netherlands B.V.
- FinlandDipentumPfizer Health Ab
- NetherlandsDipentum 500 mg, tablettenAtnahs Pharma Netherlands B.V.
- SwedenDipentum 500 mg TablettAtnahs Pharma Netherlands B.V.
- IrelandDipentum 500mg TabletsAtnahs Pharma Netherlands B.V.
- FranceDIPENTUM 500 mg, compriméATNAHS PHARMA NETHERLANDS (PAYS-BAS)
- United StatesDipentumViatris Specialty LLC
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Germany · Dipentum
- Denmark · Dipentum
- Finland · Dipentum
- France · Dipentum
- United Kingdom (Northern Ireland) · Olsalazine Sodium Atnahs Pharma Uk
- Ireland · Dipentum
- Netherlands · Dipentum
- Norway · Dipentum
- Sweden · Dipentum
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3f73524b-d137-4e4a-8cc6-9bdbd6121a66 GET /v1/drugs/3f73524b-d137-4e4a-8cc6-9bdbd6121a66?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tafla",
"source": "lyfjastofnun",
"atc_raw": "A07EC03",
"marketed": true,
"strength": "500 mg",
"ma_number": "920181",
"substance": "Olsalazinum INN natríum",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "34608"
}See everything about olsalazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.